Depo-Provera Settlement 2026: What the New Global Agreement Means for Your Claim

A global Depo-Provera settlement agreement was announced on June 15, 2026 — the most significant development in this litigation since it began. If you or a loved one used Depo-Provera injectable birth control and developed a meningioma brain tumor, this news may directly affect your right to compensation. Here is everything confirmed so far about the agreement, and what you need to do right now to protect your claim.

What Is the Depo-Provera Settlement Agreement?

On June 15, 2026, U.S. District Judge M. Casey Rodgers issued Pretrial Order No. 30A confirming that Plaintiffs’ Lead Counsel Christopher Seeger (Seeger Weiss) and defendants Pfizer Inc., Pharmacia LLC, and Pharmacia & Upjohn Co. LLC have reached a global Depo-Provera settlement agreement in principle to resolve thousands of pending meningioma claims in MDL No. 3140. This announcement marks the first major resolution framework in a litigation that has grown from 78 cases in March 2025 to more than 5,500 by June 2026.

A Depo-Provera settlement, in plain terms, is a negotiated resolution between Pfizer and claimants who allege that long-term use of the injectable birth control caused them to develop meningiomas — typically benign but potentially serious tumors of the membranes surrounding the brain or spinal cord. The goal of a global agreement is to resolve thousands of claims without requiring individual jury trials.

Confirmed facts as of June 19, 2026:

• A global agreement in principle has been reached and confirmed by the court’s own order.
• The Rule 702/Daubert general causation hearing has been postponed from June 24–25 to July 27, 2026 in Pensacola, FL while details are finalized.
• Bellwether trials previously set for December 2026 have been paused pending resolution.
• Judge Rodgers has noted the global agreement will not cover all MDL claimants — some cases will remain in active litigation.

Not yet confirmed: The official payout amounts, eligibility criteria, claims process, payout tiers, and deadlines have not been publicly released. The parties are still “memorializing the details.” No specific figure you see elsewhere should be treated as an official Pfizer offer.

What Is the Depo-Provera Lawsuit About?

Depo-Provera (medroxyprogesterone acetate) is an injectable contraceptive made by Pfizer used by millions of women for decades. Plaintiffs in the Depo-Provera lawsuit allege that long-term use significantly increases the risk of meningioma — a brain or spinal tumor that can require major surgery, radiation, and cause lasting neurological harm.

The scientific case gained major momentum from two peer-reviewed studies. A 2024 study in the British Medical Journal (BMJ) found long-term Depo-Provera users had a 5.6x increased risk of developing meningiomas. A 2025 study in JAMA Neurology, analyzing approximately 10 million women, found a 2.43x increased risk. These findings placed significant pressure on Pfizer’s defense and are widely credited with accelerating settlement discussions.

In December 2025, the U.S. Food and Drug Administration (FDA) required Pfizer to update the Depo-Provera label with an explicit meningioma warning — a regulatory action plaintiffs’ attorneys have cited as a key factor in moving the parties toward a Depo-Provera settlement. MDL No. 3140, presided over by Judge Rodgers in the Northern District of Florida, has been one of the fastest-growing pharmaceutical MDLs in the country, increasing by roughly 1,831 cases in just the 30 days before the settlement announcement, according to JPML filings.

What We Know About Depo-Provera Settlement Value So Far

Because official terms have not been released, any specific dollar amount circulating online is speculative — based on attorney commentary and comparable MDL outcomes. Here is an honest breakdown:

Confirmed: A global Depo-Provera settlement agreement exists. No official payout figures have been announced by Pfizer or the court.

Attorney estimates (speculative): Various plaintiff firms have commented publicly that individual payouts from this litigation could range from approximately $75,000 to $1.5 million or more, depending on tumor severity, treatment required, and lasting disability. These figures mirror comparable pharmaceutical MDL outcomes and should be treated as educated estimates, not guaranteed amounts.

Historical data point: Pfizer previously resolved a Canadian Depo-Provera class action involving bone density loss (a different injury) for approximately $2 million total — useful only to confirm Pfizer’s willingness to settle Depo-Provera litigation, not as a predictor of meningioma claim values.

For a deeper look at what factors drive individual claim value in this MDL, see if you may qualify for a similar recovery — our dedicated settlement amounts guide covers this litigation in detail.

Do You Qualify for the Depo-Provera Settlement?

Official eligibility criteria for the Depo-Provera settlement have not yet been published. Based on how mass tort settlements of this type are typically structured, attorneys currently evaluating claims look for these key factors:

• Meningioma diagnosis — A confirmed medical diagnosis of meningioma (brain or spinal cord) is the central injury alleged in this litigation.
• History of Depo-Provera injections — Documented use of the injectable birth control, often for 12 months or more, though shorter-term use may still be evaluated.
• Medical and pharmacy records — Records linking Depo-Provera use and meningioma diagnosis are typically required to support a claim.
• Statute of limitations — Filing deadlines generally run 2–3 years from diagnosis or discovery. With settlement talks active, acting quickly is critical.
• Wrongful death claims — Surviving family members may qualify if a loved one died from a Depo-Provera-linked meningioma.

Judge Rodgers has made clear the global agreement will not cover every MDL claimant. Speaking with an attorney now gives you the best chance to understand exactly where your claim stands — and whether it falls inside or outside the settlement framework. You may also qualify for other active mass tort lawsuits TortAdvisor tracks nationwide.

How Much Could Your Depo-Provera Settlement Be Worth?

The value of an individual claim in this Depo-Provera settlement depends on a combination of medical, financial, and legal factors. No official tiers have been announced, but attorneys evaluating cases weigh several key elements. To get a personalized estimate, estimate what your case could be worth now using our settlement calculator.

Tumor severity is one of the strongest value drivers. A large meningioma requiring emergency surgery, causing lasting cognitive or neurological impairment, or recurring after initial treatment is likely to command substantially higher compensation. The scope of medical treatment — surgery, radiation therapy, hospitalization, and specialist follow-up — directly affects both economic damages and the overall strength of a claim.

Lost income and reduced earning capacity are also major factors, particularly for claimants in their peak working years at the time of diagnosis. Neurological effects from meningioma and its treatment can permanently limit a person’s ability to work — courts and settlement administrators weigh this heavily in comparable mass tort cases. Duration of Depo-Provera use matters too: the science links extended use (typically three or more years) with the most significantly elevated risk, which can strengthen causation arguments and increase claim value.

What Happens Next in the Depo-Provera MDL?

The path from “agreement in principle” to actual payments typically takes several months in a mass tort of this scale. The parties must reduce the Depo-Provera settlement to a formal written agreement — specifying payout tiers, eligibility criteria, a claims administration process, and submission deadlines. This can take weeks to months after the initial announcement.

Daubert hearing — July 27, 2026: The Rule 702/Daubert general causation hearing was postponed from its original June 24–25 date to July 27, 2026 in Pensacola, FL while the agreement is finalized. If a complete settlement is reached before that date, the hearing may be vacated entirely. If finalization takes longer, the hearing will proceed and could significantly affect the trajectory of any remaining litigation.

Claimants outside the settlement: Judge Rodgers has stated clearly that the global framework will not resolve every MDL claim. Those whose cases fall outside — whether due to injury type, timing, or other factors — will remain in active litigation and proceed toward the bellwether trial phase once the settlement picture is clearer.

Act now, before deadlines are set: Mass tort settlement frameworks routinely establish early filing or registration deadlines, and claimants who engage counsel before criteria are formalized are generally better positioned. Statutes of limitations also continue to run during settlement negotiations. If you have a meningioma diagnosis linked to Depo-Provera use, contacting an attorney today — even before official terms are released — is the single most important step you can take.

Frequently Asked Questions

Related Articles